Findings from Shaheed Beheshti University of Medical Sciences Reveals New Findings on Ulcerative Colitis (The Effects of Two Vitamin D Regimens On Ulcerative Colitis Activity Index, Quality of Life and Oxidant/anti-oxidant Status)
Clinical Trials Daily
2019 APR 23 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Daily -- Fresh data on Digestive System Diseases and Conditions - Ulcerative Colitis are presented in a new report. According to news originating from Tehran, Iran, by NewsRx correspondents, research stated, “The optimum dosage for vitamin D supplementation has not yet been elucidated in patients with Ulcerative colitis (UC). The aim of this study was to investigate the effects of two vitamin D regimens in UC patients with vitamin D deficiency.”
Financial support for this research came from Shahid Beheshti University of Medical Science.
Our news journalists obtained a quote from the research from the Shaheed Beheshti University of Medical Sciences, “In this double blind randomized clinical trial, 50 patients with mild to moderate UC, who met inclusion criteria, received either 1000 or 2000 IU/day of vitamin D (as low dose or high dose group, respectively) for 12 weeks. Serum 25-hydroxy vitamin D (25-OHD) level, total antioxidant capacity (TAC), and Total Oxidant Status (TOS), the inflammatory bowel disease questionnaire - 9 (IBDQ-9) score and the Simple Clinical Colitis Activity Index Questionnaire (SCCAI) score were assessed before and after intervention. At the end of study, serum 25-OHD levels significantly increased in the high dose group (P < 0.001) and the increase was significantly more than low dose group (6.7 +/- 3.8 ng/mL in the high dose group versus 0.2 +/- 0.5 ng/mL in the low dose group) (P < 0.001). Serum TOS concentration decreased significantly (- 0.37 +/- 0.26) only in the high dose group (P value = 0.023). There was no statistically significant change in serum TAC between two groups during the study. IBDQ-9 mean score significantly increased in high dose group compared to the low dose group (P value = 0.001) and SCCAI score in both groups reduced (- 2.58 +/- 2.16 and - 0.9 +/- 0.3 in high dose and low dose respectively), while this reduction was significant only in the high dose group (P value ae >0.001). Our results indicate that 2000 IU daily dose of vitamin D can increase serum 25-OHD concentration, and quality of life, while it reduces disease activity in UC patients with vitamin D deficiency.”
According to the news editors, the research concluded: “We recommend assessment of the vitamin D status in all patients with UC because they may benefit from vitamin D therapy.”
For more information on this research see: The Effects of Two Vitamin D Regimens On Ulcerative Colitis Activity Index, Quality of Life and Oxidant/anti-oxidant Status. Nutrition Journal, 2019;18():. Nutrition Journal can be contacted at: Bmc, Campus, 4 Crinan St, London N1 9XW, England. (BioMed Central - http://www.biomedcentral.com/; Nutrition Journal - www.nutritionj.com)
The news correspondents report that additional information may be obtained from A. Hekmatdoost, Shaheed Beheshti University of Medical Sciences, Research Institute, Faculty of Nutrition Sciences and Food Technology, Dept. of Clinical Nutrition and Dietetics, Natl Nutr & Food Technol, Tehran, Iran. Additional authors for this research include S. Karimi, Z. Yari, S. Tabataba-vakili, F. Alborzi, N. Ebrahimi-Daryani and M. Hedayati.
The direct object identifier (DOI) for that additional information is: https://doi.org/10.1186/s12937-019-0441-7. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.
(Our reports deliver fact-based news of research and discoveries from around the world.)